(Q61936838)
Statements
An Open Label Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Treatment of Diffuse Systemic Sclerosis (English)
0 references
February 2010
0 references
July 2016
0 references
15
0 references
19 year
0 references
90 year
0 references